Efficacy and survival analysis of neoadjuvant chemotherapy combined with immunotherapy in locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction
Preliminary results indicate that nCI shows promising efficacy in the treatment of resectable locally advanced Siewert type II AEG, with high rates of pCR and MPR, as well as good tolerance and safety. 3-4 cycles of nCI may provide better therapeutic efficacy than 1-2 cycles. These findings require confirmation in prospective head-to-head trials to establish potential long-term clinical benefits.
Authors
- Cong Feng (ORCID: https://orcid.org/0000-0002-4855-0023)
- Huilai Lv (ORCID: https://orcid.org/0000-0002-2795-9751)
- Bokang Sun
- Chunyue Gai
- Fan Zhang (ORCID: https://orcid.org/0009-0002-8365-3340)
- Ziqiang Tian (ORCID: https://orcid.org/0000-0002-3091-313X)
- Hao Wang (ORCID: https://orcid.org/0000-0002-0901-5183)
- Xiaohan Zhao (ORCID: https://orcid.org/0000-0002-6957-7639)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei Science and Technology Department (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fonc.2025.1642996
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00